GLTO Quote, Financials, Valuation and Earnings

Lyell Immunopharma, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -258973.33%. Galecto, Inc.'s return on equity of -123.72% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 47.63%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 16.89%. Given that Galecto, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Galecto, Inc. is more attractive than Lyell Immunopharma, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Lyell Immunopharma, Inc. quarterly revenues of $15K. Galecto, Inc.'s net income of -$3.1M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 92,033.08x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Metagenomi Therapeutics, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -235.51%. Galecto, Inc.'s return on equity of -123.72% beat Metagenomi Therapeutics, Inc.'s return on equity of -41.18%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 47.63%. On the other hand Metagenomi Therapeutics, Inc. has an analysts' consensus of $9.33 which suggests that it could grow by 543.68%. Given that Metagenomi Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Metagenomi Therapeutics, Inc. is more attractive than Galecto, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Metagenomi Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Metagenomi Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Metagenomi Therapeutics, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Metagenomi Therapeutics, Inc. quarterly revenues of $8.7M. Galecto, Inc.'s net income of -$3.1M is higher than Metagenomi Therapeutics, Inc.'s net income of -$20.4M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Metagenomi Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 1.75x for Metagenomi Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -9210.61%. Galecto, Inc.'s return on equity of -123.72% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 47.63%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 169.93%. Given that Ovid Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Galecto, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.621%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Galecto, Inc.'s net income of -$3.1M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 16.13x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of 21.74%. Galecto, Inc.'s return on equity of -123.72% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Galecto, Inc. has a consensus price target of $44.33, signalling upside risk potential of 47.63%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $867.85 which suggests that it could grow by 10.74%. Given that Galecto, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Galecto, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Galecto, Inc. has a beta of 1.422, which suggesting that the stock is 42.247% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Galecto, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galecto, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Galecto, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.